In a recent clinical study of individuals with COVID-19, ruxolitinib, a JAK1/2 inhibitor, was not significantly superior to placebo in terms of clinical parameters, although faster recovery from lymphopenia was observed (Cao et al., 2020b). Here, JAK1 is linked to COVID-19.